GlobeNewswire·Oct 15, 2026, 3:30 AM ET

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

iOnctura appointed Paul Sekhri as Chair of its Board of Directors with immediate effect on October 15, 2026.
Sekhri brings over 35 years of experience in life sciences, including roles as CEO of eGenesis, Lycera, Cerimon, ARIAD, Sanofi, Teva, Veeva Systems, Vtv Therapeutics, Apnimed, Resolution Therapeutics, Violet Therapeutics, \& Longboard Pharmaceuticals.
The appointment strengthens the board with expertise in company building, strategic transactions, financing, \& board leadership across more than 40 public, private, \& non-profit organizations.
iOnctura is advancing roginolisib into late-stage development with two randomized studies fully enrolled following the completion of OCULE-01 in December 2025 \& PULMO-01 in January 2026.
CEO Catherine Pickering highlighted Sekhri's capital markets expertise as vital for iOnctura's Phase III growth phase while thanking outgoing Chair Dr. Mark Velleca.
Sekhri emphasized roginolisib's unique ability to lock PI3Kδ in its inactive state, noting strong survival signals in uveal melanoma \& the critical nature of upcoming clinical readouts.
Roginolisib is a first-in-class conformation-selective PI3Kδ inhibitor showing potential to deliver clinical activity without the tolerability issues seen in previous generations.
The company is backed by institutional investors including Syncona, M Ventures, Inkef Capital, EIC Fund, VI Partners, Schroders Capital, \& XGEN Venture.